Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
 
 
For period ending 20 February 2018
 
GlaxoSmithKline plc
(Name of registrant)
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 
 
Form 20-F x     Form 40-F
 
--
 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
 
Yes      No x
 
 
 GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
12,482 (Deferred)
 
 
£0.0000
8,614 (Matching)
 
 
 
 
 
d)
Aggregated information
21,096
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1563
 5,868 (Deferred)
 
 
£13.1563
 4,050 (Matching)
 
 
 
 
 
d)
Aggregated information
9,918
Aggregated volume Price
£13.1563
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
9,142 (Deferred)
 
 
£0.0000
6,308 (Matching)
 
 
 
 
 
d)
Aggregated information
15,450
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R Connor
 
b)
Position/status
President, Global Manufacturing & Supply
 
c)
Initial notification/
amendment
Initial Notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1028
4,384 (Deferred)
 
 
£13.1200
3,026 (Matching)
 
 
 
 
 
d)
Aggregated information
7,410
 
Aggregated volume Price
£13.1114
 
e)
Date of the transaction
2018-02-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
17,435 (Deferred)
 
 
£0.0000
12,030 (Matching)
 
 
 
 
 
d)
Aggregated information
29,465
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr S Dingemans
 
b)
Position/status
Chief Financial Officer
 
c)
Initial notification/
amendment
Initial Notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1236
8,360 (Deferred)
 
 
£13.1230
5,768 (Matching)
 
 
 
 
 
d)
Aggregated information
14,128
 
Aggregated volume Price
£13.1233
 
e)
Date of the transaction
2018-02-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics and Compliance
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
6,402 (Deferred)
 
 
£0.0000
4,418 (Matching)
 
 
 
 
 
d)
Aggregated information
 10,820
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr N Hirons
 
b)
Position/status
SVP, Global Ethics and Compliance
 
c)
Initial notification/
amendment
Initial Notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1068
3,070 (Deferred)
 
 
£13.1118
2,120 (Matching)
 
 
 
 
 
d)
Aggregated information
 5,190
 
Aggregated volume Price
£13.1093
 
e)
Date of the transaction
2018-02-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 

 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
10,258 (Deferred)
 
 
£0.0000
7,078 (Matching)
 
 
 
 
 
d)
Aggregated information
 17,336
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr D Redfern
 
b)
Position/status
Chief Strategy Officer
 
c)
Initial notification/
amendment
Initial Notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1800
4,822 (Deferred)
 
 
£13.1800
3,328 (Matching)
 
 
 
 
 
d)
Aggregated information
 8,150
 
Aggregated volume Price
£13.1800
 
e)
Date of the transaction
2018-02-16
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
13,805 (Deferred)
 
 
£0.0000
9,525 (Matching)
 
 
 
 
 
d)
Aggregated information
 23,330
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1180
6,489 (Deferred)
 
 
£13.1180
4,478 (Matching)
 
 
 
 
 
d)
Aggregated information
 10,967
Aggregated volume Price
£13.1180
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
4,689 (Deferred)
 
 
£0.0000
3,235 (Matching)
 
 
 
 
 
d)
Aggregated information
 7,924
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-19
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1240
2,204 (Deferred)
 
 
£13.1240
1,521 (Matching)
 
 
 
 
 
d)
Aggregated information
 3,725
Aggregated volume Price
£13.1240
e)
Date of the transaction
2018-02-19
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P Vallance
b)
Position/status
Outgoing President, R&D
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£0.0000
20,322 (Deferred)
 
 
£0.0000
14,022 (Matching)
 
 
 
 
 
d)
Aggregated information
 34,344
Aggregated volume Price
£0.0000
e)
Date of the transaction
2018-02-19
f)
Place of the transaction
 
n/a
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P Vallance
b)
Position/status
Outgoing President, R&D
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£13.1760
20,322 (Deferred)
 
 
£13.1760
14,022 (Matching)
 
 
 
 
 
d)
Aggregated information
 34,344
Aggregated volume Price
£13.1180
e)
Date of the transaction
2018-02-19
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 20, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc